Brought to you by 
XDx brings in $26.5mm with Series E round
19 Mar 2013
Executive Summary
Molecular diagnostics company XDx has completed its Series E financing round, bringing in $26.5mm. Led by Duff Ackerman & Goodrich, additional investors included Intel Capital and existing backers Kleiner Perkins Caufield & Byers, Texas Pacific Group Ventures, Sprout Group (managed by New Leaf Venture Partners), Burrill & Co., Integral Capital, and Bay Area Equity Fund (managed by JP Morgan).
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com